Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
By R. Motzer, Thomas E. Hutson, D. Cella, J. Reeves, R. Hawkins, Jun Guo, P. Nathan, M. Staehler, Paul de Souza, J. Merchan and 15 more. New England Journal of Medicine, 2013
1,778 citations recorded by the source corpus.
Subfields: Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/02bdbccbc4f8cc4ac3b4b5e880e767af52b0a445
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Renal cell carcinoma (2017, background): “Furthermore, pazopanib has been shown not to be inferior to sunitinib in a large phase III trial [44].”
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “recent phase III trial comparing sunitinib with pazopanib has demonstrated that both drugs have similar efficacy [15] and single agent therapy with either drug is now recommended as standard of care in the first-line in mRCC.”
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “5 mth NS Reduced 4 [122]”
- Cabozantinib versus everolimus in advanced renal cell carcinoma (2015, neutral): “Abdominal pain 53 (16) 12 (4) 31 (10) 4 (1)”
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines (2016, background): “These drugs induce cardiac dysfunction in 3–15% of patients and symptomatic HF in 1–10% of patients.(61) – 64 Other anti-VEGF inhibitors such as sorafenib and vandetanib also induce cardiac dysfunction, but prospective data from large clinical trials are missing.”
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (2018, neutral): “Hypertension 12 (2) 4 (<1) 216 (40) 85 (16)”
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “Furthermore, pazopanib has been shown not to be inferior to sunitinib in a large phase III trial [44].”
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. (2017, result): “6 months and 18%, respectively, were lower than those reported in previous trials that included patients of all risk groups, including favorable risk.(7,8) For example, median PFS per investigator was 10.”
- Systemic therapy in metastatic renal cell carcinoma (2016, background): “In summary, treatment options for mRCC have expanded enormously, since the introduction of targeted therapies, and have significantly extended the survival of mRCC patients—OS can be prolonged by up to 32 months by sequencing different approved targeted drugs [20, 23, 39]—but the availability of num”
- Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations (2020, background): “The risk of HF is highest in the initial stages of therapy with anti-VEGF agents,(145) and >10% of patients on sorafenib, sunitinib and pazopanib will develop LVSD on treatment.(146,147)”
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, background): “Furthermore, pazopanib has been shown not to be inferior to sunitinib in a large phase III trial [44].”